Software Compliance in Regulatory Engineering

I have years of software and AI regulatory compliance experience, and here's a framework that I've put together to simplify your life and reduce your regulatory risk. 👇 As of late March 2026, the global regulatory landscape for AI software and agents has shifted from abstract principles to strict, verifiable deliverables. Between the EU AI Act’s risk tiering, the FDA’s Predetermined Change Control Plans (PCCP), NIST’s AI RMF, and the stringent data lineage requirements of ISO/IEC 42001—keeping up has become a massive bottleneck for innovation (trust me, I do this every day). If your team is trying to satisfy these requirements piecemeal, you are bleeding time and resources. To cut through the noise, I developed the Universal AI Software Deployment Framework (2026 Edition). It synthesizes the overlapping focus areas of major global regulations into a practical, industry-agnostic 4-Phase process: 1️⃣ Foundation & Context: Defining strict boundaries and Context of Use (CoU). 2️⃣ Data & Governance: Ensuring traceable data lineage and measurable bias mitigation. 3️⃣ Validation & Guardrails: Executing adversarial simulation and defining acceptable bounds for updates. 4️⃣ Deployment & Monitor: Activating live Human-in-the-Loop oversight and incident response. 💡 The Core Value: This is a single, unified framework that enables multi-domain compliance. Whether you are deploying an internal LLM agent or a high-risk, customer-facing machine learning tool, following this exact sequence ensures you are simultaneously checking the boxes for the EU, the US (FDA/NIST), and international ISO standards. Build the guardrails once; deploy globally. Check out the attached PDF for the full breakdown, including the targeted guardrail dimensions and immediate next steps for structural alignment (like forming your AI Ethics Board and drafting your PCCP templates). Let me know in the comments—which phase is currently the biggest hurdle for your organization? #AICompliance #ArtificialIntelligence #EUAIAct #NIST #ISO42001 #MachineLearning #TechLaw #Innovation #RegTech #DataGovernance

If your medical device includes firmware, embedded software, a mobile app, or cloud connectivity… IEC 62304 applies.⚙️ And regulators are not asking whether your software works when everything goes right. They want proof it behaves safely when things go wrong. Software safety classification is not a label. Class A, B, and C define the rigor of your entire development lifecycle. Class C means architectural depth, traceable requirements, unit and integration testing, fault injection, configuration control, anomaly tracking, and objective verification of every software based risk control. Regulators expect evidence: - Reproducible builds. - Documented code reviews. - Test results under worst case conditions. IEC 62304 is not about perfect code. It is about proving the system transitions to a safe state when sensors fail, data corrupts, or unexpected conditions occur. Software must align with ISO 14971 risk management and IEC 62366 usability. If software contributes to a hazard, the mitigation must be designed, traceable, and verified. Many startups build functional prototypes. Fewer build safety classified, regulatory ready software architectures. We break down what actually matters in the full video. 🧠 #MedTech #IEC62304 #MedicalDevices #EmbeddedSystems #RegulatoryStrategy #ISO14971 #MedTechMan

Great devices ship when RA and engineering build together 🤝 Regulatory can feel like a moving target for tech teams. The cure is not more paperwork. It is shared structure. Treat compliance as a product feature: clear intended use, clean design inputs, linked risks, and evidence that matches what you claim. When RA sits inside the build loop, teams move faster and avoid late surprises from NBs or FDA. Practical moves that work: ↳ Embed an RA partner in sprint planning and backlog grooming. ↳ Write design inputs with acceptance criteria that cite the rule or standard. ↳ Keep a simple trace matrix that links user needs, risks, tests, and GSPR or 21 CFR clauses. ↳ Schedule quick risk check-ins at every design review. ↳ Freeze claims and IFU language before verification starts. ↳ Run a pre-submission file skim together and fix gaps early.

Finally! The EU MDCG has delivered the regulatory clarity we've been waiting for Digital Health and Apps Stores in the EU. The new MDCG 2025-4 Guidance on Medical Device Software Apps officially confirms what many of us have been advocating: Apple and Google are now explicitly classified as Medical Device Software Distributors under EU MDR & IVDR Article 14 because of their Apps Stores. This means both tech giants bear legal liability for medical device software apps distributed through their platforms. No more regulatory grey zone. 𝐖𝐡𝐚𝐭 𝐓𝐡𝐢𝐬 𝐂𝐡𝐚𝐧𝐠𝐞𝐬: For Platform Operators: - Legal responsibility to ensure proper MDR/IVDR compliance before allowing medical device apps on their stores - Obligation to verify manufacturer compliance documentation - Potential liability for non-compliant medical device software distribution For SaMD Developers: - Clearer regulatory pathway with defined distributor responsibilities - no loss of connection to their patients - Reduced compliance uncertainty when launching digital therapeutics - should they use app stores or not? - Platform operators now share accountability in the medical device supply chain - closing the gap on traceability to better protect people from harmful and faulty Digital Health apps. The guidance specifically addresses section 3.2, establishing that major app stores cannot simply act as neutral platforms when distributing medical device software. They're now active participants in the regulatory framework. This development fundamentally shifts how digital health solutions reach patients. Every digital therapeutics company, SaMD developer, and health app creator now operates under a framework where Apple and Google must actively ensure medical device compliance. 𝐓𝐡𝐞 𝐑𝐞𝐚𝐥𝐢𝐭𝐲 𝐂𝐡𝐞𝐜𝐤: While this provides much-needed clarity, implementation will be complex. How will these platforms verify compliance? What review processes will they establish? The next 12 months will be critical as both sides adapt to these new obligations. Would we see the same interpretation in the EU, UK, or AUS? At Complear, we've been preparing for this regulatory evolution. We're developing digital tools to help both platforms and manufacturers navigate these new distributor obligations efficiently. We are witnessing a new era of software accountability, with even Big Tech platforms having to comply with everyone else's rules, and assume their critical role in medical device distribution of Digital Health. #MDCG #MedicalDevices #SaMD #DigitalHealth #MDR #IVDR #RegulatoryCompliance

🚫 Stop Over-Validating Software in Medical Device Quality Systems I continue to see medical device manufacturers struggling with an overly complex approach to software validation. All too often, GAMP® 5—a framework designed primarily for pharmaceutical manufacturing systems—is applied by default. The result? 🔹 Excessive documentation 🔹 Long validation timelines 🔹 High costs with limited added compliance value 👉 Software validation for medical devices should be risk-based. There are established, regulator-recognized tools specifically designed for medical device quality management systems (QMS), including: ISO/TR 80002-2 (software validation for medical devices) and FDA Computer Software Assurance (CSA) guidance. These approaches align with ISO 13485, 21 CFR Part 820, and FDA expectations—while enabling a far more efficient and pragmatic validation strategy. Are these methods as exhaustive as GAMP® 5? No. Are they appropriate, defensible, and compliant for many medical device software applications? Yes. 📊 Recently, I used these approaches to validate: Temperature monitoring system → validation planning completed in 6 hours. Mid-sized ERP system → validation planning completed in 14 hours. The outcome: compliant software validation, reduced effort, and faster deployment—without compromising patient safety or regulatory expectations. If you’re working in Quality Assurance, Regulatory Affairs, CSV, or Digital Transformation and want to modernize your software validation approach, feel free to connect or reach out.

Lifecycle Regulatory Requirements for SaMD in Europe This analysis examines how the EU regulatory framework—MDR 2017/745 and associated standards—maps onto every phase of the Software as a Medical Device (SaMD) lifecycle. It identifies how lifecycle-based oversight shapes development predictability, certification complexity, and long-term maintenance obligations for software-driven medical technologies. Key Takeaways: 1️⃣ Lifecycle compliance relies on a multi-standard architecture. The paper shows that MDR, ISO 14971, ISO 13485, IEC 62304, IEC 62366 and IEC 82304 must be applied together across development, maintenance and post-market phases, forming an integrated compliance stack rather than isolated requirements. 2️⃣ Rule 11 drives higher-risk classification for software. Under MDR Annex VIII Rule 11, many software products transition to higher risk classes, triggering more complex conformity assessment processes and third-party notified-body involvement. 3️⃣ Maintenance and change control are major regulatory burdens. The authors highlight that adaptive, corrective and preventive updates require structured change-control, re-validation when needed, and risk reassessment—making post-market phases as resource-intensive as development. 4️⃣ Post-market surveillance is continuous and multi-layered. PMS requirements include incident reporting, usability monitoring, cybersecurity management, UDI traceability and updates to technical documentation, embedding ongoing regulatory obligations throughout the product lifecycle. Synthesis: The authors conclude that SaMD regulation is fragmented across standards, but becomes coherent when mapped onto lifecycle stages. They identify key risks stemming from unaligned processes, insufficient early planning, and the growing regulatory impact of iterative software modifications. They recommend lifecycle-integrated planning using MDR-aligned standards, structured risk and usability processes, and rigorous post-market surveillance to maintain safety, performance and compliance. ➡️ How should investors factor lifecycle-wide compliance and change-control obligations into valuation models for SaMD companies? 🔗 Source(s): Navigating Regulatory Challenges Across the Life Cycle of a SaMD. Francesconi M., et al. Journal of Biomedical Informatics, 2025. #digitalhealth #healthinvesting #venturecapital #healthcareinnovation #governance

Does your device connect to a hospital network or EHR? A joint effort between ISO's Technical Committee 215 (ISO/TC 215) and IEC's Sub-Committee 62A (IEC/SC 62A) has met this month. Joint Working Group 7 focuses on safe, effective, and secure health software and health IT systems, including medical devices: ISO Health Informatics [TC 215] The Strategic Context: https://hubs.li/Q040m4F00 - Part 1 (81001-1): Foundational terminology (Published) - Part 4-1 (81001-4-1): Healthcare delivery organization (HDO) implementation and clinical use risk management (Work Item / Committee Draft) - Part 5-1 (81001-5-1): Manufacturer lifecycle security requirements (Published 2021) Three Strategic Implications: 1. Scope Redefinition: The title evolution signals regulatory focus has migrated from network infrastructure to software systems and clinical workflow integration as the primary risk domain. - Previous: "Application of risk management for IT-networks incorporating medical devices" - Current: "Health software and health IT systems safety, effectiveness and security—Part 4-1: Application of risk management in the Implementation and Clinical Use" 2. Manufacturer-HDO Interdependency: While 81001-4-1 formally addresses HDO responsibilities, manufacturer compliance has become a critical enabler. FDA expectations increasingly require device manufacturers to provide: - Security capability documentation (MDS2 forms) - Software Bills of Materials (SBOMs) - Implementation guidance enabling HDO compliance with 81001-4-1 Manufacturers that fail to provide adequate security documentation create downstream HDO compliance barriers that constrain market access. 3. Standards redesignation triggers systematic documentation updates across: - Quality management system procedures - Regulatory submission templates - Risk management documentation - Supplier quality agreements - Customer-facing technical specifications At Innolitics, we've integrated IEC 81001-5-1 cybersecurity requirements across multiple FDA submissions and maintain real-time tracking of the IEC 80001 → ISO 81001 transition within our regulatory guidance infrastructure and client deliverable templates. This proactive standards monitoring ensures submission documents reference current nomenclature, preventing avoidable regulatory review delays. Next Steps: Evaluate your device's security capability documentation against evolving FDA expectations → https://hubs.li/Q040m76N0 #MedicalDevices #Standards #ISO81001 #IEC80001 #FDA510k #Cybersecurity #RegulatoryStrategy

AI itself does not trigger validation. Validation is driven by intended use and determinism. This is the fundamental shift in the MedTech regulatory landscape as we move into 2026. While many organizations remain paralyzed by the myth that any AI deployed in a Quality Management System (QMS) requires full classical validation, the reality is that regulatory burdens must scale based on the specific variables of the tool. Navigating how to handle AI agents, such as those used for SOP compliance evaluation, requires a risk-based approach that aligns with the harmonized FDA Quality Management System Regulation (QMSR), the EU AI Act, and ISO 13485:2016. The regulatory expectation scales across three distinct profiles: ▪️ The Research Aid: A general-purpose LLM relying on pre-training knowledge for advisory support. Because it acts as an informational research aid and does not operate as a controlled part of the QMS, formal validation is not required. ▪️ The Grounded Assistant: An agent referencing controlled regulatory text to provide more authoritative outputs. This profile directly influences quality system decisions, shifting the requirement toward Software Assurance under Computer Software Assurance (CSA) principles rather than full classical validation. ▪️ The Logic-Driven Auditor: An agent executing repeatable, deterministic criteria to perform compliance assessments. When the agent becomes a controlled, repeatable element of the quality system, full validation is required to demonstrate the correct application of criteria and intended use fulfillment. The strategy for 2026 is clear: don't let the technology alone dictate your compliance roadmap. If your AI remains an advisory, human-reviewed support tool, risk-based assurance is sufficient. Only when it moves toward autonomous, deterministic execution does the threshold for full validation apply. #AI #CSA #DigitalQuality #AdaptiveQualitySystems

Six months behind. Legally mandated deadline. Failure meant regulatory penalties, audits, & legal exposure. No pressure. A regulatory compliance program was supposed to start 12 months before the deadline. But when I stepped in, it hadn’t even begun. Six months had already been lost. The project was stuck in a dangerous loop: > Regulatory language was vague and open to interpretation > Teams were resisting the effort > Requirements weren’t defined > Leadership alignment didn’t exist > No one owned the path forward Meanwhile the legal deadline wasn’t moving. This wasn’t a project. It was a potential regulatory crisis. So the first step wasn’t planning. It was stabilization. The program required someone operating across multiple roles simultaneously: > Program recovery > Requirements translation > Architectural coordination, > Executive alignment under extreme time pressure. I shifted into recovery mode & rebuilt the program from the ground up. 1️⃣Rapid stakeholder mobilization We brought legal, architecture, engineering, & business leaders together to translate regulatory language into clear tech & operational requirements. Ambiguity had been the blocker. Clarity unlocked execution. 2️⃣Adaptive governance The teams involved operated in very different delivery models, & required direct executive alignment. Instead of forcing a framework, I built an adaptive governance structure that connected teams & ELT through: > Executive communication and decision checkpoints > A formal C-suite SteerCo > Clear escalation paths > Shared milestones tied to the regulatory deadline This removed fragmentation, ensuring technical execution & executive risk management stayed aligned. 3️⃣Iterative requirements refinement Regulatory language rarely translates cleanly into systems. I ran structured refinement sessions to: > Identify compliance requirements > Validate technical feasibility > Architect controls that satisfied both regulatory & operational needs This turned vague mandates into executable workstreams. 4️⃣Non-negotiable approval gates Under extreme timeline pressure, teams often skip validation. We did the opposite. Critical approvals were built into the program to ensure: > Compliance alignment > Architectural integrity > Audit defensibility Speed without rigor would have created bigger risks later. THE RESULT Despite starting six months late, the program delivered before the legal deadline. > Zero regulatory penalties > Zero audit defects > No legal exposure > No additional budget required The difference wasn’t working harder. It was turning regulatory ambiguity into executable workstreams & decisions. And the biggest risk? It wasn’t the timeline.  It was lack of ownership. Leadership isn’t about managing tasks. It’s about creating clarity fast enough for the organization to execute. And once someone owns the problem, translates the requirements & aligns leadership… Execution follows. ___  ♻️ Repost 🔔 Follow Elizabeth Dworkin